Blocking hyperactive androgen receptor signaling ameliorates cardiac and renal hypertrophy in Fabry mice

Human Molecular Genetics

Volumn 24, Issue 11, 2014, Pages 3181-3191

  Shen, Jin Song ^a   Meng, Xing Li ^a   Wight Carter, Mary ^b   Day, Taniqua S ^a   Goetsch, Sean C ^c   Forni, Sabrina ^a   Schneider, Jay W ^c   Liu, Zhi Ping ^c   Schiffmann, Raphael ^a  

^a BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; ANDROGEN RECEPTOR; ATRIAL NATRIURETIC FACTOR; BETA GLUCURONIDASE; BRAIN NATRIURETIC PEPTIDE; CREATININE; GLYCOSPHINGOLIPID; MESSENGER RNA; MYOSIN HEAVY CHAIN ALPHA; MYOSIN HEAVY CHAIN BETA; SERINE; SOMATOMEDIN C; TESTOSTERONE; THREONINE; TRANSFORMING GROWTH FACTOR BETA1; ANDROGEN RECEPTOR ANTAGONIST;

ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CASTRATED MALE; CASTRATION; CREATININE BLOOD LEVEL; CREATININE URINE LEVEL; ENZYME ACTIVITY; FABRY DISEASE; FEMALE; GENE EXPRESSION; HEART LEFT VENTRICLE WALL; HEART MUSCLE CELL; HEART VENTRICLE HYPERTROPHY; HISTOLOGY; HUMAN; HUMAN CELL; KIDNEY HYPERTROPHY; KIDNEY MASS; KIDNEY PROXIMAL TUBULE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; RECEPTOR DOWN REGULATION; SIGNAL TRANSDUCTION; TESTIS WEIGHT; TESTOSTERONE BLOOD LEVEL; TRANSTHORACIC ECHOCARDIOGRAPHY; UREA NITROGEN BLOOD LEVEL; 129 MOUSE; ANIMAL; C57BL MOUSE; GENETIC TRANSCRIPTION; GENETICS; HYPERTROPHY, LEFT VENTRICULAR; KIDNEY; KIDNEY DISEASES; METABOLISM; PATHOLOGY; TRANSGENIC MOUSE;

MUS;

ANDROGEN RECEPTOR ANTAGONISTS; ANIMALS; FABRY DISEASE; FEMALE; HYPERTROPHY, LEFT VENTRICULAR; KIDNEY; KIDNEY DISEASES; MALE; MICE, 129 STRAIN; MICE, INBRED C57BL; MICE, TRANSGENIC; RECEPTORS, ANDROGEN; SIGNAL TRANSDUCTION; TRANSCRIPTION, GENETIC;

EID: 84930741305     PISSN: 09646906     EISSN: 14602083     Source Type: Journal    
DOI: 10.1093/hmg/ddv070     Document Type: Article

References (54)

1. Brady, R., Gal, A.E., Bradley, R.M., Martensson, E.,Warshaw, A. L. and Laster, L. (1967) Enzymatic defect in Fabry disease: ceramide trihexosidase deficiency. N. Engl. J. Med., 276, 1163-1167.
2. Desnick, R.J., Ioannou, Y.A. and Eng, C.M. (2001) In Scriver, C. R., Beaudet, A.L., Sly,W.S. and Valle, D. (eds), The Metabolic and Molecular Bases of Inherited Disease. McGraw-Hill, NewYork, pp. 3733-3774.
3. Schiffmann, R. (2009) Fabry disease. Pharmacol. Ther., 122, 65-77.
4. Weidemann, F., Niemann, M., Warnock, D.G., Ertl, G. and Wanner, C. (2011) The Fabry cardiomyopathy: models for the cardiologist. Annu. Rev. Med., 62, 59-67.
5. Stiennon, M. and Goldberg, M.E. (1980) Renal size in Fabry's disease. Urol. Radiol., 2, 17-21.
6. Wang, R.Y., Lelis, A., Mirocha, J. and Wilcox, W.R. (2007) Heterozygous Fabry women are not just carriers, but have a significant burden of disease and impaired quality of life. Genet. Med., 9, 34-45.
7. Pastores, G.M. (2007) Agalsidase alfa (Replagal) in the treatment of Anderson-Fabry disease. Biologics, 1, 291-300.
8. Weidemann, F., Niemann, M., Breunig, F., Herrmann, S., Beer, M., Stork, S., Voelker,W., Ertl, G.,Wanner, C. and Strotmann, J. (2009) Long-term effects of enzyme replacement therapy on fabry cardiomyopathy: evidence for a better outcome with early treatment. Circulation, 119, 524-529.
9. Tondel, C., Bostad, L., Larsen, K.K., Hirth, A., Vikse, B.E., Houge, G. and Svarstad, E. (2013) Agalsidase benefits renal histology in young patients with Fabry disease. J. Am. Soc. Nephrol., 24, 137-148.
10. Moore, D.F., Scott, L.T., Gladwin, M.T., Altarescu, G., Kaneski, C., Suzuki, K., Pease-Fye, M., Ferri, R., Brady, R. O., Herscovitch, P. et al. (2001) Regional cerebral hyperperfusion and nitric oxide pathway dysregulation in Fabry disease:reversal by enzyme replacement therapy. Circulation, 104, 1506-1512.
11. Shu, L., Park, J.L., Byun, J., Pennathur, S., Kollmeyer, J. and Shayman, J.A. (2009) Decreased nitric oxide bioavailability in a mouse model of Fabry disease. J. Am. Soc. Nephrol., 20, 1975-1985.
12. Aerts, J.M., Groener, J.E., Kuiper, S., Donker-Koopman, W.E., Strijland, A., Ottenhoff, R., van Roomen, C., Mirzaian, M.,Wijburg, F.A., Linthorst, G.E. et al. (2008) Elevated globotriaosylsphingosine is a hallmark of Fabry disease. Proc. Natl. Acad. Sci. USA, 105, 2812-2817.
13. Chevrier, M., Brakch, N., Celine, L., Genty, D., Ramdani, Y., Moll, S., Djavaheri-Mergny, M., Brasse-Lagnel, C., Annie Laquerriere, A.L., Barbey, F. et al. (2010) Autophagosome maturation is impaired in Fabry disease. Autophagy, 6, 589-599.
14. Ohshima, T., Murray, G.J., Swaim, W.D., Longenecker, G., Quirk, J.M., Cardarelli, C.O., Sugimoto, Y., Pastan, I., Gottesman, M.M., Brady, R.O. et al. (1997) Alpha-galactosidase A deficient mice: a model of Fabry disease. Proc. Natl. Acad. Sci. USA, 94, 2540-2544.
15. Matsui, T., Li, L., Wu, J.C., Cook, S.A., Nagoshi, T., Picard, M.H., Liao, R. and Rosenzweig, A. (2002) Phenotypic spectrum caused by transgenic overexpression of activated Akt in the heart. J. Biol. Chem., 277, 22896-22901.
16. Marsh, J.D., Lehmann, M.H., Ritchie, R.H., Gwathmey, J.K., Green, G.E. and Schiebinger, R.J. (1998) Androgen receptors mediate hypertrophy in cardiac myocytes. Circulation, 98, 256-261.
17. Nahrendorf, M., Frantz, S., Hu, K., von zur Muhlen, C., Tomaszewski, M., Scheuermann, H., Kaiser, R., Jazbutyte, V., Beer, S., Bauer, W. et al. (2003) Effect of testosterone on post-myocardial infarction remodeling and function. Cardiovasc. Res., 57, 370-378.
18. Koenig, H., Goldstone, A., Blume, G. and Lu, C.Y. (1980) Testosterone- mediated sexual dimorphism of mitochondria and lysosomes in mouse kidney proximal tubules. Science, 209, 1023-1026.
19. Berger, F.G. and Watson, G. (1989) Androgen-regulated gene expression. Annu. Rev. Physiol., 51, 51-65.
20. Wang, R.S., Yeh, S., Tzeng, C.R. and Chang, C. (2009) Androgen receptor roles in spermatogenesis and fertility: lessons from testicular cell-specific androgen receptor knockout mice. Endocr. Rev., 30, 119-132.
21. Singh, R., Artaza, J.N., Taylor,W.E., Braga, M., Yuan, X., Gonzalez-Cadavid, N.F. and Bhasin, S. (2006) Testosterone inhibits adipogenic differentiation in 3T3-L1 cells: nuclear translocation of androgen receptor complex with beta-catenin and T-cell factor 4 may bypass canonical Wnt signaling to down-regulate adipogenic transcription factors. Endocrinology, 147, 141-154.
22. Fan, W., Yanase, T., Nomura, M., Okabe, T., Goto, K., Sato, T., Kawano, H., Kato, S. and Nawata, H. (2005) Androgen receptor null male mice develop late-onset obesity caused by decreased energy expenditure and lipolytic activity but show normal insulin sensitivity with high adiponectin secretion. Diabetes, 54, 1000-1008.
23. Heinlein, C.A. and Chang, C. (2002) Androgen receptor (AR) coregulators: an overview. Endocr. Rev., 23, 175-200.
24. Wu, Y., Zhao,W., Zhao, J., Pan, J., Wu, Q., Zhang, Y., Bauman, W.A. and Cardozo, C.P. (2007) Identification of androgen response elements in the insulin-like growth factor I upstream promoter. Endocrinology, 148, 2984-2993.
25. Chipuk, J.E., Cornelius, S.C., Pultz, N.J., Jorgensen, J.S., Bonham, M.J., Kim, S.J. and Danielpour, D. (2002) The androgen receptor represses transforming growth factor-beta signaling through interaction with Smad3. J. Biol. Chem., 277, 1240-1248.
26. Melia, M.J., Bofill, N., Hubank, M. and Meseguer, A. (1998) Identification of androgen-regulated genes in mouse kidney by representational difference analysis and random arbitrarily primed polymerase chain reaction. Endocrinology, 139, 688-695.
27. Hartig, P.C., Bobseine, K.L., Britt, B.H., Cardon, M.C., Lambright, C.R., Wilson, V.S. and Gray, L.E. Jr. (2002) Development of two androgen receptor assays using adenoviral transduction of MMTV-luc reporter and/or hAR for endocrine screening. Toxicol. Sci., 66, 82-90.
28. Shen, J.S., Meng, X.L., Moore, D.F., Quirk, J.M., Shayman, J.A., Schiffmann, R. and Kaneski, C.R. (2008) Globotriaosylceramide induces oxidative stress and up-regulates cell adhesion molecule expression in Fabry disease endothelial cells. Mol. Genet. Metab., 95, 163-168.
29. Riegman, P.H., Vlietstra, R.J., van der Korput, J.A., Brinkmann, A.O. and Trapman, J. (1991) The promoter of the prostate-specific antigen gene contains a functional androgen responsive element. Mol. Endocrinol., 5, 1921-1930.
30. Claycomb,W.C., Lanson, N.A. Jr., Stallworth, B.S., Egeland, D. B., Delcarpio, J.B., Bahinski, A. and Izzo, N.J. Jr. (1998) HL-1 cells: a cardiac muscle cell line that contracts and retains phenotypic characteristics of the adult cardiomyocyte. Proc. Natl. Acad. Sci. USA, 95, 2979-2984.
31. Puri, V.,Watanabe, R., Dominguez, M., Sun, X., Wheatley, C.L., Marks, D.L. and Pagano, R.E. (1999) Cholesterol modulates membrane traffic along the endocytic pathway in sphingolipid- storage diseases. Nat. Cell Biol., 1, 386-388.
32. McCluer, R.H., Williams, M.A., Gross, S.K. and Meisler, M.H. (1981) Testosterone effects on the induction and urinary excretion of mouse kidney glycosphingolipids associated with lysosomes. J. Biol. Chem., 256, 13112-13120.
33. Platt, F.M., Boland, B. and van der Spoel, A.C. (2012) The cell biology of disease: lysosomal storage disorders: the cellular impact of lysosomal dysfunction. J. Cell Biol., 199, 723-734.
34. Cox, T.M. and Cachon-Gonzalez, M.B. (2012) The cellular pathology of lysosomal diseases. J. Pathol., 226, 241-254.
35. Walkley, S.U. (2009) Pathogenic cascades in lysosomal disease-Why so complex?. J. Inherit. Metab. Dis., 32, 181-189.
36. Ikeda, Y., Aihara, K., Sato, T., Akaike, M., Yoshizumi, M., Suzaki, Y., Izawa, Y., Fujimura, M., Hashizume, S., Kato, M. et al. (2005) Androgen receptor gene knockout male mice exhibit impaired cardiac growth and exacerbation of angiotensin IIinduced cardiac fibrosis. J. Biol. Chem., 280, 29661-29666.
37. McMullen, J.R. and Jennings, G.L. (2007) Differences between pathological and physiological cardiac hypertrophy: novel therapeutic strategies to treat heart failure. Clin. Exp. Pharmacol. Physiol., 34, 255-262.
38. Tang, S.C. and Lai, K.N. (2012) The pathogenic role of the renal proximal tubular cell in diabetic nephropathy. Nephrol. Dial. Transplant., 27, 3049-3056.
39. Taguchi, A., Maruyama, H., Nameta, M., Yamamoto, T., Matsuda, J., Kulkarni, A.B., Yoshioka, H. and Ishii, S. (2013) A symptomatic Fabry disease mouse model generated by inducing globotriaosylceramide synthesis. Biochem. J., 456, 373-383.
40. Dart, D.A., Waxman, J., Aboagye, E.O. and Bevan, C.L. (2013) Visualising androgen receptor activity in male and female mice. PLoS ONE, 8, e71694.
41. Meseguer, A. and Catterall, J.F. (1992) Effects of pituitary hormones on the cell-specific expression of the KAP gene. Mol. Cell. Endocrinol., 89, 153-162.
42. Bangari, D.S., Ashe, K.M., Desnick, R.J., Maloney, C., Lydon, J., Piepenhagen, P., Budman, E., Leonard, J.P., Cheng, S.H., Marshall, J. et al. (2015) Alpha-galactosidase A knockout mice:progressive organ pathology resembles the type 2 lateronset phenotype of fabry disease. Am. J. Pathol, 185, 651-665.
43. Koryakina, Y., Ta, H.Q. and Gioeli, D. (2014) Androgen receptor phosphorylation: biological context and functional consequences. Endocr. Relat. Cancer, 21, T131-T145.
44. Kung, H.J. and Evans, C.P. (2009) Oncogenic activation of androgen receptor. Urol. Oncol., 27, 48-52.
45. Takane, K.K. and McPhaul, M.J. (1996) Functional analysis of the human androgen receptor promoter. Mol. Cell. Endocrinol., 119, 83-93.
46. Mizokami, A., Yeh, S.Y. and Chang, C. (1994) Identification of 3′,5′-cyclic adenosine monophosphate response element and other cis-acting elements in the human androgen receptor gene promoter. Mol. Endocrinol., 8, 77-88.
47. Yang, L., Xie, S., Jamaluddin, M.S., Altuwaijri, S., Ni, J., Kim, E., Chen, Y.T., Hu, Y.C.,Wang, L., Chuang, K.H. et al. (2005) Induction of androgen receptor expression by phosphatidylinositol 3-kinase/Akt downstream substrate, FOXO3a, and their roles in apoptosis of LNCaP prostate cancer cells. J. Biol. Chem., 280, 33558-33565.
48. Yang, X., Chen,M.W., Terry, S., Vacherot, F., Bemis, D.L., Capodice, J., Kitajewski, J., de la Taille, A., Benson, M.C., Guo, Y. et al. (2006) Complex regulation of human androgen receptor expression by Wnt signaling in prostate cancer cells. Oncogene, 25, 3436-3444.
49. Kemppainen, J.A. andWilson, E.M. (1996) Agonist and antagonist activities of hydroxyflutamide and Casodex relate to androgen receptor stabilization. Urology, 48, 157-163.
50. Tran, C., Ouk, S., Clegg, N.J., Chen, Y., Watson, P.A., Arora, V., Wongvipat, J., Smith-Jones, P.M., Yoo, D., Kwon, A. et al. (2009) Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science, 324, 787-790.
51. Chen, Y., Sawyers, C.L. and Scher, H.I. (2008) Targeting the androgen receptor pathway in prostate cancer. Curr. Opin. Pharmacol., 8, 440-448.
52. Meng, X.L., Eto, Y., Schiffmann, R. and Shen, J.S. (2013) HIV Tat domain improves cross-correction of human galactocerebrosidase in a gene- and flanking sequence-dependent manner. Mol. Ther. Nucleic Acids, 2, e130.
53. Breggia, A.C. and Himmelfarb, J. (2008) Primary mouse renal tubular epithelial cells have variable injury tolerance to ischemic and chemical mediators of oxidative stress. Oxid. Med. Cell. Longev., 1, 33-38.
54. Durant, B., Forni, S., Sweetman, L., Brignol, N., Meng, X.L., Benjamin, E.R., Schiffmann, R. and Shen, J.S. (2011) Sex differences of urinary and kidney globotriaosylceramide and lyso-globotriaosylceramide in Fabry mice. J. Lipid Res., 52, 1742-1746.